Market Place
Sourcing Support
Polaryx Reaffirms Commitment to Rare Pediatric Disorders
27 Feb 2026 //
GLOBENEWSWIRE
Polaryx Pharma Chooses CRO For SOTERIA Ph2 Basket Trial
17 Feb 2026 //
GLOBENEWSWIRE
Polaryx Reveals SOTERIA Pre-Clinical Data At 22nd Worldsymposium
10 Feb 2026 //
GLOBENEWSWIRE
Polaryx Therapeutics Welcomes Members of the Board of Directors
05 Feb 2026 //
GLOBENEWSWIRE
Polaryx Unveils SOTERIA Late-Breaker at 22nd WORLD Symposium
03 Feb 2026 //
GLOBENEWSWIRE
Polaryx Therapeutics to List on Nasdaq as PLYX
02 Feb 2026 //
GLOBENEWSWIRE
Polaryx Therapeutics Secures Nasdaq Nod for Common Stock
30 Jan 2026 //
GLOBENEWSWIRE
Polaryx Announces FDA Grants Orphan Drug Designation for PLX-200
30 Aug 2021 //
PRNEWSWIRE
Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug
11 Feb 2021 //
PRNEWSWIRE
Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan
10 Feb 2021 //
PRNEWSWIRE
Polaryx Receives Both Rare Pediatric Disease and Orphan Drug Designations
18 Dec 2020 //
PRNEWSWIRE
Polaryx Receives Both Rare Pediatric Disease and Orphan Drug Designations
18 Dec 2020 //
PRNEWSWIRE
Polaryx Receives Both Rare Pediatric Disease and ODD
25 Nov 2020 //
PRNEWSWIRE
Polaryx Receives Both Rare Pediatric Disease and Orphan Drug Designations
24 Nov 2020 //
PRNEWSWIRE
Polaryx Therapeutics Receives FDA Fast Track Designation to PLX-200
20 Aug 2020 //
PRNEWSWIRE
Polaryx Therapeutics Receives IND Approval From the FDA to Study PLX-200
08 Apr 2020 //
PRNEWSWIRE
Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA
20 Jan 2020 //
PR NEWS WIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.